glp-1 microbiome Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy Bidirectional Interactions Between the Gut

A supplement cites a percentage increase in GLP-1 levels without clearly stating the data comes from mouse or rat studies

Available from: European Medicines Agency (EMA)

The 'Switch' is On: Proving the Viability of Oral Maintenance Therapy The ATTAIN-MAINTAIN study was a first-of-its-kind Phase 3 trial designed to answer a critical clinical question: can patients who have successfully lost weight on injectable GLP-1s (Wegovy or Zepbound) switch directly to an oral agent and maintain their results

Glucose-lowering therapy beyond insulin in type 1 diabetes: a narrative review on existing evidence from randomized controlled trials and clinical perspective